Iimveliso

Iindlela zokunyanga i-T2DM, isifo esibonakaliswe yintlupheko ephindwe kabini ye-islet cell dysfunction kunye nokumelana ne-insulin, zibandakanya ii-agent ezandisa i-secretion ye-insulin yi-pancreas (i-secretagogues), i-agents ezandisa uvakalelo lwezitho ezijoliswe kuyo kwi-insulin (i-sensitizers), kunye ii-agent ezinciphisa izinga lokufunxa i-glucose ukusuka kwi-gastrointestinal tract.I-Liraglutide, i-GLP-1 i-receptor agonist ukufikelela kwimarike, ine-97% ye-homology kwi-GLP-1 kunye neenguqu ezimbini ze-amino acid kunye nokongezwa kwekhonkco le-asidi enamafutha.Ngokukodwa, i-lysine kwindawo ye-34 ithathelwe indawo ye-arginine, kwaye i-lysine kwindawo ye-26 iguqulwe nge-C16 acyl chain nge-glutamoyl spacer.ILiraglutide ifumana ukuchasana kwayo nokuthotywa kwe-DPP-4 ukusuka ekuthambekeni kwayo ukwenza iimicelles kunye nokubophelela kwi-albumin.Ngokungafaniyo ne-exenatide yangaphambili, efuna iinaliti ezimbini zemihla ngemihla ngaphambi kwesidlo sokuqala nesokugqibela sosuku, i-liraglutide ivunyiwe njengerejimeni yonyango kanye yonke imihla kwaye inokusetyenziswa ngokudityaniswa ne-metformin okanye i-sulfonylurea kwizigulana ezinolawulo olungonelanga lwe-glycemic kunye nokuba i-monotherapy okanye unyango oludibeneyo oludibeneyo.Ikwavunywa ngokudibeneyo kunye nonyango olubini lwe-metformin kunye ne-thiazolidinedione kwizigulane ezinokulawulwa kwe-glycemic eyaneleyo.I-Liraglutide ibonise amandla okubopha i-61 pM (EC50 = 55 pM ye-GLP-1) kwi-receptors ye-GLP-1 edibeneyo yomntu.